BioAegis Therapeutics Unveils Upcoming Clinical Study of
BioAegis announces global Phase 2 study of its inflammation regulator protein, gelsolin, for the treatment of Acute Respiratory Distress Syndrome (ARDS). ...
Source: globenewswire.com
L 1b News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from L 1b. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In L 1b Today - Breaking & Trending Today
BioAegis Therapeutics Awarded $20 Million BARDA DRIVe
Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for...
Source: globenewswire.com
Frontiers | The One That Got Away: How Macrophage-Derived IL-1β Escapes the Mycolactone-Dependent Sec61 Blockade in Buruli Ulcer
Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a devastating necrotizing skin disease. Key to its pathogenesis is mycolactone, the exotoxin virulence factor that is both immunosuppressive and cytotoxic. The discovery that the essential Sec61 translocon is the major cellular target of mycolactone explains much of the disease pathology, including the immune blockade. Sec61 inhibition leads to a loss in production of nearly all cytokines from monocytes, macrophages, dendritic cells and T cells, as well as antigen presentation pathway proteins and costimulatory molecules. However, there h...
Source: frontiersin.org